Tamsulosin Phase III Clinical Trial -Double-Blind, Placebo Controlled Study in Female Patients With Lower Urinary Tract Syndrome
Phase 3
Completed
- Conditions
- Urinary Tract Diseases
- Registration Number
- NCT00239265
- Lead Sponsor
- Astellas Pharma Inc
- Brief Summary
The purpose of this study is to determine whether Tamuslosin is effective in the treatment of lower urinary tract syndrome with female patients.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- Female
- Target Recruitment
- Not specified
Inclusion Criteria
- Patients with urination disorder not accompanied by apparent organic or neurologic abnormality(lower urinary tract syndrome: LUTs)．
Exclusion Criteria
- Patients with urination disorder accompanied by apparent organic or neurologic abnormality, active urinary tract infections, severe cardiovascular, hepatic and/or kidney complications.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie tamsulosin's efficacy in treating lower urinary tract syndrome in females?
How does tamsulosin compare to standard-of-care treatments for female lower urinary tract symptoms in phase III trials?
Are there specific biomarkers that predict response to tamsulosin in female patients with bladder dysfunction?
What are the most common adverse events associated with tamsulosin use in female urology patients and how are they managed?
What alternative alpha-blocker therapies or combination approaches are being explored for female lower urinary tract syndrome treatment?